New drug MT-251 put to first safety test in healthy people
NCT ID NCT07423299
First seen Feb 26, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This early-phase study tests the safety and tolerability of a new drug called MT-251 in 70 healthy adults aged 19 to 55. Participants receive either the drug or a placebo to monitor side effects and how the body processes the drug. No treatment benefit is expected; the goal is to gather essential safety data before testing in patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mirador Clinical Department
RECRUITINGSan Diego, California, 92121, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.